These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 35659376)

  • 21. Cardiovascular toxic effects of antitumor agents: Pathogenetic mechanisms.
    Pantazi D; Tselepis AD
    Thromb Res; 2022 May; 213 Suppl 1():S95-S102. PubMed ID: 36210569
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Organization and implementation of a cardio-oncology program.
    Fiuza M; Ribeiro L; Magalhães A; Sousa AR; Nobre Menezes M; Jorge M; Costa L; Pinto FJ
    Rev Port Cardiol; 2016 Sep; 35(9):485-94. PubMed ID: 27503589
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Cardiac and vascular toxicity of chemotherapies].
    Ederhy S; Ancedy Y; Champiat S; Lopez-Trabada-Ataz D; Dulery R; Cohen A
    Rev Prat; 2018 Mar; 68(3):326-329. PubMed ID: 30869300
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [MODERN ASPECTS OF DIAGNOSIS AND TREATMENT OF HEART FAILURE, AS A MANIFESTATION OF ANTHRACYCLINE CARDIOTOXICITY (REVIEW)].
    Saganelidze K; Kavtaradze N
    Georgian Med News; 2018 May; (278):87-93. PubMed ID: 29905551
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of sacubitril/valsartan in the treatment of middle-aged and elderly patients with hypertension: a systematic review and meta-analysis of randomized controlled trials.
    Wu HX; Liu KK; Li BN; Liu S; Jin JC
    Ann Palliat Med; 2022 May; 11(5):1811-1825. PubMed ID: 35672897
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Exposure to anthracyclines during childhood causes cardiac injury.
    Lipshultz SE
    Semin Oncol; 2006 Jun; 33(3 Suppl 8):S8-14. PubMed ID: 16781284
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anthracycline-associated cardiotoxicity in survivors of childhood cancer.
    Trachtenberg BH; Landy DC; Franco VI; Henkel JM; Pearson EJ; Miller TL; Lipshultz SE
    Pediatr Cardiol; 2011 Mar; 32(3):342-53. PubMed ID: 21221562
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Risk assessment and management of anthracycline and HER2 receptor inhibitor-induced cardiomyopathy.
    Jahangir E; Shah S; Shum K; Baxter C; Fitzpatrick JD; Cole J; Gilliland Y; Polin NM
    South Med J; 2015 Feb; 108(2):71-8. PubMed ID: 25688890
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cardiotoxicity of anticancer treatments: what the cardiologist needs to know.
    Ewer MS; Ewer SM
    Nat Rev Cardiol; 2010 Oct; 7(10):564-75. PubMed ID: 20842180
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anthracycline-Induced Cardiotoxicity in Young Cancer Patients: The Role of Carnitine.
    Armenian SH
    Ann Nutr Metab; 2016; 68 Suppl 3():10-14. PubMed ID: 27931027
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cardiotoxicity of anthracycline in young breast cancer female patients: the possibility of detection of early cardiotoxicity by TDI.
    Nagy AC; Tolnay E; Nagykálnai T; Forster T
    Neoplasma; 2006; 53(6):511-7. PubMed ID: 17167721
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Management of Cancer Therapeutics-Related Cardiac Dysfunction.
    Vallakati A; Konda B; Lenihan DJ; Baliga RR
    Heart Fail Clin; 2018 Oct; 14(4):553-567. PubMed ID: 30266364
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [ACE inhibitors in the treatment of ventricular dysfunction caused by cardiotoxic cytostatics].
    Mladosievicová B
    Ceska Slov Farm; 2004 Mar; 53(2):55-60. PubMed ID: 15095572
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Trastuzumab and target-therapy side effects: Is still valid to differentiate anthracycline Type I from Type II cardiomyopathies?
    Riccio G; Coppola C; Piscopo G; Capasso I; Maurea C; Esposito E; De Lorenzo C; Maurea N
    Hum Vaccin Immunother; 2016 May; 12(5):1124-31. PubMed ID: 26836985
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cardio-oncology: the new frontier of clinical and preventive cardiology.
    Paris S; Tarantini L; Navazio A; Faggiano P
    Monaldi Arch Chest Dis; 2020 Jun; 90(2):. PubMed ID: 32571000
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparing Sacubitril/Valsartan Against Sodium-Glucose Cotransporter 2 Inhibitors in Heart Failure: A Systematic Review and Network Meta-analysis.
    Teo YN; Teo YH; Syn NL; Yoong CSY; Cheong AJY; Wee CF; Lim YC; Lee CH; Yeo TC; Chai P; Wong RCC; Lin W; Sia CH
    Clin Drug Investig; 2022 Jan; 42(1):1-16. PubMed ID: 34797518
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Predicting and Preventing Anthracycline-Related Cardiotoxicity.
    Armenian S; Bhatia S
    Am Soc Clin Oncol Educ Book; 2018 May; 38():3-12. PubMed ID: 30231396
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anthracycline-related cardiotoxicity in childhood cancer survivors.
    Lipshultz SE; Karnik R; Sambatakos P; Franco VI; Ross SW; Miller TL
    Curr Opin Cardiol; 2014 Jan; 29(1):103-12. PubMed ID: 24284979
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dexrazoxane for the prevention of cardiomyopathy in anthracycline treated pediatric cancer patients.
    Anderson B
    Pediatr Blood Cancer; 2005 Jun; 44(7):584-8. PubMed ID: 15700251
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anthracycline-Induced Cardiotoxicity: Time to Focus on Cardioprotection Again.
    Croft AJ; Ngo DTM; Sverdlov AL
    Heart Lung Circ; 2019 Oct; 28(10):1454-1456. PubMed ID: 31495502
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.